Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (J.E.E., J.M.).
Center for Cardiovascular Analytics, Research and Data Science, Providence Heart Institute, Providence St. Joseph Health, Portland, OR (T.J.G., S.T.C.).
Hypertension. 2023 Sep;80(9):1845-1855. doi: 10.1161/HYPERTENSIONAHA.123.20894. Epub 2023 Jun 26.
Apparent resistant hypertension (aRH) carries excess cardiovascular risk beyond nonresistant forms of hypertension; however, our understanding of this at-risk population, as defined by current US practice guidelines, is limited. Accordingly, we sought to evaluate the prevalence, clinical characteristics, and pharmacotherapeutic patterns of patients with aRH using contemporary blood pressure guidance.
We classified patients at 3 large healthcare systems by hypertensive status using contemporary hypertension guidelines. We subsequently described the demographic and clinical characteristics of patients with aRH and compared these factors among hypertensive patients without aRH and between those with controlled and uncontrolled aRH.
A total of 2 420 468 patients were analyzed, of whom 1 343 489 (55.6%) were hypertensive according to contemporary guidelines. Among hypertensive patients, 11 992 (8.5%) met criteria for aRH, with nearly all assessed comorbid conditions, particularly diabetes and heart failure, being more common in those with aRH. When compared with patients with uncontrolled aRH, those with controlled aRH were more frequently prescribed a beta-blocker, diuretic, and nitrate, with the largest standardized difference observed for a mineralocorticoid receptor antagonist (35.4% versus 10.4%, Cohen D 0.62). Consistent findings were noted in sensitivity analyses using the blood pressure threshold of 140/90 mm Hg.
In an analysis of over 2.4 million individuals, a lower prevalence of aRH was observed than previously reported (12%-15%), but with a high burden of comorbidities. Identification of differences in pharmacotherapy between patients with controlled and uncontrolled aRH, particularly lower rates of mineralocorticoid receptor antagonist use, help define potential opportunities to improve care and lower cardiovascular risk.
显性难治性高血压(aRH)比非难治性高血压形式具有更高的心血管风险;然而,我们对这一高危人群的了解,根据当前的美国实践指南,是有限的。因此,我们试图使用当代血压指导来评估患有 aRH 的患者的患病率、临床特征和药物治疗模式。
我们使用当代高血压指南,根据高血压状态对 3 个大型医疗保健系统的患者进行分类。随后,我们描述了 aRH 患者的人口统计学和临床特征,并比较了无 aRH 的高血压患者之间以及控制和未控制的 aRH 患者之间的这些因素。
共分析了 2420468 名患者,其中根据当代指南,1343489 名(55.6%)患有高血压。在高血压患者中,有 11992 名(8.5%)符合 aRH 的标准,几乎所有评估的合并症,特别是糖尿病和心力衰竭,在 aRH 患者中更为常见。与未控制的 aRH 患者相比,控制的 aRH 患者更频繁地服用β受体阻滞剂、利尿剂和硝酸盐,其中观察到最大的标准化差异是用于治疗的醛固酮受体拮抗剂(35.4%对 10.4%,Cohen D 0.62)。在使用血压阈值为 140/90mmHg 的敏感性分析中也观察到了一致的结果。
在对超过 240 万人的分析中,观察到 aRH 的患病率低于以前报告的(12%-15%),但合并症负担较高。识别控制和未控制的 aRH 患者之间药物治疗的差异,特别是醛固酮受体拮抗剂使用率较低,有助于确定改善护理和降低心血管风险的潜在机会。